• Follow the Money: Cloud R&D, Generative Biology, Robotics

    Bio-IT World | Platforms for machine-learning generative biology and cloud R&D, drug delivery chip for therapies at the tumor site, and AI-driven drug discovery and robotics.

    Dec 2, 2021
  • Cloud Hygiene and Cost Optimization at Johnson & Johnson

    Bio-IT World | TRENDS FROM THE TRENCHES—Tom Messina has worked in various roles for Johnson & Johnson dating back to 1999 and is currently an IT Director in J&J’s Pharmaceutical R&D division, Janssen. BioTeam had a chance to speak with Tom recently to appreciate how J&J is leveraging cloud compute and storage resources to maximize innovation and growth while controlling costs.

    Dec 1, 2021
  • Gilead Chooses AWS, Illumina, Sequoia Fund Chinese Startups, More

    Bio-IT World | Illumina powers the Canadian COVID-19 Genomics Network, organ-on-a-chip explores infectious disease, and cell analysis acquisitions. Plus new products from PerkinElmer, Bio-Rad, Roswell Biotechnologies, Genialis, and more.

    Nov 30, 2021
  • Building the Data Foundation for Faster Time to Science in Healthcare

    Bio-IT World | Genomics and artificial intelligence (AI) are key to this quest and at-scale advancement of personalized medicine. Both, however, require liquid data and modern data infrastructure that re-imagines the role of data and how it is used.

    Nov 23, 2021
  • Gut Microbiome Linked To Aggressive Prostate Cancer

    Bio-IT World | Evidence has been mounting for decades that what men eat can lower or raise their risk of prostate cancer—including aggressive forms of the disease that can be lethal. But that’s only part of the story.

    Nov 22, 2021
  • Biopharma’s Dark Data Problem

    Bio-IT World | Worldwide spending on pharmaceutical R&D will reach $230 billion by 2026. So with investment dollars flowing in and R&D continuing an upward trajectory all should be well, right? Well… not exactly. Like many industries, pharmaceutical companies are facing a data problem—a dark data problem.

    Nov 19, 2021
  • Recursion’s Vision for the New Shape of Drug Discovery

    Bio-IT World | As a “digital native,” Recursion is working to reshape the drug discovery industry—quite literally. Gone is the vision of a traditional discovery funnel, wide at the top and slowly narrowing. Instead, Recursion proposes a drug discovery machine powering a T-shaped funnel where many options are considered, but failure is fast and the candidates that advance have a potentially higher likelihood of being a successful treatment. Easier said than done.

    Nov 17, 2021
  • Unique Repurposing Approach Identifies Potential Alzheimer’s Disease Drug

    Bio-IT World | Trials for Alzheimer’s disease (AD) drugs have repeatedly failed with billions of dollars invested. But a new, multidisciplinary drug repurposing model, described in a recent article in Nature Aging, combines drug repurposing with precision medicine, network-based drug targeting, induced pluripotent stem cell (iPSC) technology, and real-world data analysis.

    Nov 16, 2021
  • MemVerge’s Vision for Big Memory Computing

    Bio-IT World | The vision, Charles Fan explains, is big memory. Fan and two other co-founders launched MemVerge, an all-memory storage start-up that Fan calls quite disruptive and high risk—but also the compute architecture of the future.

    Nov 11, 2021
  • What’s Behind Growing Adoption Of Cell-Based Vaccine Platforms

    Bio-IT World | Cell-based vaccines, initially developed to add speed and scale to pandemic response efforts and reduce dependency on chickens in the vaccine manufacturing process, have over the past few years also shown to be more reliably effective than traditional, egg-based products.

    Nov 10, 2021
  • NVIDIA GTC: Networking, Healthcare AI, Modeling and Simulation

    Bio-IT World | At the NVIDIA GTC event, wide ranging announcements covered new networking capabilities, new AI capabilities, and new tools to advance healthcare and life sciences research.

    Nov 9, 2021
  • Genetic Sequencing Will Enable Us To Win The Global Battle Against COVID-19

    Bio-IT World | Using genetic sequencing to identify pathogens and respond to outbreaks is hardly new. The emergence of the SARS-CoV-2 in late 2019 was a game-changer, however. While SARS-CoV-2 was identified and sequenced in record time, it proved impossible to contain. It quickly became apparent that existing surveillance systems were not up to the task of tracking a fast-moving virus that spread asymptomatically. The speed and scale of Coronavirus spread provided a wake-up call highlighting our vulnerability to a global pandemic. But bioinformatics plays a crucial role.

    Nov 5, 2021
  • ‘Reverse Vaccination’ Has Broad Clinical Potential As Immunotherapy Strategy

    Bio-IT World | Researchers at the University of Buffalo (UB) have come up with a nanoparticle platform for oral prophylactic immunotherapy designed to pre-expose the immune system to medications it might otherwise perceive as foreign and attack. If translated to the clinic, their novel “reverse vaccination” approach could be used to desensitize patients to key proteins in drug treatments for rare conditions, autoimmune diseases, and allergies.

    Nov 3, 2021
  • Follow the Money: CRISPR, Data Science in Africa, Analytics Cloud

    Bio-IT World | CRISPR partnership with Vertex Pharmaceuticals, new public biotech fund, life sciences analytics cloud, immune target validation, single cell analysis, and more.

    Nov 2, 2021
  • Broad Optimizes for Google Cloud, Intel and Seven Bridges Population Genomics Tool, More

    Bio-IT World | Pistoia sets new life sciences strategy, Charles River Labs announces cryo-EM partnership, and Vertex and Mammoth launch CRISPR partnership. Plus new products from Waters, PerkinElmer, Thermo Scientific and more.

    Oct 29, 2021
  • Artificial Intelligence Aiding Human Interpretation Of Sequenced Genomes

    Bio-IT World | A “quiet revolution” has been underway over the past year, exponentially growing the number of genetic variants discoverable by genome sequencing, according to Stephen Kingsmore, M.D., president and CEO of Rady Children's Institute for Genomic Medicine in San Diego. Notably, it is now possible to identify an enormous number of structural variants—large genomic alterations that include insertions, deletions, and copy number variations—which account for about 20% of diagnoses in the neonatal intensive care unit (NICU).

    Oct 28, 2021
  • Takeda’s Krista McKee on Shifting the Data Ecosystem

    Bio-IT World | Krista McKee’s 20-year career in pharma has steadily taken her on a trajectory toward data science. She is currently Head of Insights and Analytics at Takeda’s Data Sciences Institute (DSI). She recently sat down to discuss how Takeda is recognizing the importance of data alignment and accessibility and the choreography necessary to keep it all moving forward.

    Oct 26, 2021
  • New Discovery Data Architecture Needed to Support New Modalities

    Bio-IT World | Increasingly, the discovery and development of new medicines is embracing bioactive modalities beyond traditional small molecules, both as therapeutic agents and delivery mechanisms. I propose that the industry create standards that describe not only how experimental and substance data should be treated but also cover the services that provide access to that data.

    Oct 22, 2021
  • UC Berkeley, UCSF Launch Computational Precision Health Program

    Bio-IT World | Funded by an anonymous $50 million gift, the University of California, Berkeley and UC San Francisco yesterday announced a joint program in computational precision health.

    Oct 21, 2021
  • Janssen’s Data Ecosystem and the Role of Data Managers

    Bio-IT World | At the Bio-IT World Conference & Expo last month, Aleksandar Stojmirovic and Weiwei Schultz, both of Janssen’s Data Science group, explained the data management mission and vision of Janssen R&D.

    Oct 20, 2021